{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:52:57Z","timestamp":1788457977152,"version":"build-2803163510"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Amsterdam UMC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00198-019-05234-w","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T02:02:27Z","timestamp":1575943347000},"page":"637-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Perspective on skeletal health in inflammatory bowel disease"],"prefix":"10.1007","volume":"31","author":[{"given":"A. A.","family":"van Bodegraven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5050-2584","authenticated-orcid":false,"given":"N.","family":"Bravenboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"5234_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","volume":"12","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN (2015) Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 12:205\u2013217","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5234_CR2","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/ecco-jcc\/jjx055","volume":"11","author":"TRA van den Heuvel","year":"2017","unstructured":"van den Heuvel TRA, Jeuring SFG, Zeegers MP, van Dongen D, Wolters A, Masclee AAM, Hameeteman WH, Romberg-Camps MJL, Oostenbrug LE, Pierik MJ, Jonkers DM (2017) A 20-year temporal change analysis in incidence, presenting phenotype and mortality, in the Dutch IBDSL cohort-can diagnostic factors explain the increase in IBD incidence? J Crohns Colitis 11:1169\u20131179","journal-title":"J Crohns Colitis"},{"key":"5234_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/ajg.2008.38","volume":"104","author":"MJ Romberg-Camps","year":"2009","unstructured":"Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink-van de Kruijs M, Cilissen M, Engels LG, van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbr\u00fcgger RW (2009) Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 104:371\u2013383","journal-title":"Am J Gastroenterol"},{"key":"5234_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.7326\/0003-4819-133-10-200011210-00012","volume":"133","author":"CN Bernstein","year":"2000","unstructured":"Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN (2000) The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 133:795\u2013799","journal-title":"Ann Intern Med"},{"key":"5234_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/aje\/kwf007","volume":"156","author":"P Vestergaard","year":"2002","unstructured":"Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn\u2019s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 156:1\u201310","journal-title":"Am J Epidemiol"},{"key":"5234_CR6","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1053\/j.gastro.2003.09.027","volume":"125","author":"TP van Staa","year":"2003","unstructured":"van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK (2003) Inflammatory bowel disease and the risk of fracture. Gastroenterology 125:1591\u20131597","journal-title":"Gastroenterology"},{"key":"5234_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/gut.2003.026799","volume":"53","author":"T Card","year":"2004","unstructured":"Card T, West J, Hubbard R, Logan RF (2004) Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 53:251\u2013255","journal-title":"Gut"},{"key":"5234_CR8","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/ibd.21472","volume":"17","author":"MD Kappelman","year":"2011","unstructured":"Kappelman MD, Galanko JA, Porter CQ, Sandler RS (2011) Risk of diagnosed fractures in children with inflammatory bowel diseases. Inflamm Bowel Dis 17:1125\u20131130","journal-title":"Inflamm Bowel Dis"},{"key":"5234_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/ijcp.12526","volume":"69","author":"MS Tsai","year":"2015","unstructured":"Tsai MS, Lin CL, Tu YK, Lee PH, Kao CH (2015) Risks and predictors of osteoporosis in patients with inflammatory bowel diseases in an Asian population: a nationwide population-based cohort study. Int J Clin Pract 69:235\u2013241","journal-title":"Int J Clin Pract"},{"key":"5234_CR10","doi-asserted-by":"crossref","unstructured":"Szafors P, Che H, Barnetche T, Morel J, Gaujoux-Viala C, Combe B, Lukas C (2018) Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int","DOI":"10.1136\/annrheumdis-2018-eular.2553"},{"key":"5234_CR11","doi-asserted-by":"crossref","unstructured":"Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A (2018) Risk of fractures in inflammatory bowel diseases: a systematic review and meta-analysis. J Clin Gastroenterol","DOI":"10.1097\/MCG.0000000000001031"},{"key":"5234_CR12","doi-asserted-by":"crossref","unstructured":"Ferrari S, Bianchi ML, Eisman JA, Foldes AJ, Adami S, Wahl DA, Stepan JJ, de Vernejoul MC, Kaufman JM, Pathophysiology IOFCoSAWGoO (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 23:2735\u20132748","DOI":"10.1007\/s00198-012-2030-x"},{"key":"5234_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/00054725-199811000-00002","volume":"4","author":"C Schulte","year":"1998","unstructured":"Schulte C, Dignass AU, Mann K, Goebell H (1998) Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 4:268\u2013275","journal-title":"Inflamm Bowel Dis"},{"key":"5234_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","volume":"10","author":"C Ott","year":"2013","unstructured":"Ott C, Scholmerich J (2013) Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 10:585\u2013595","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5234_CR15","unstructured":"Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S, Veereman-Wauters G, Chevaux JB, Allez M, Danese S, Sturm A, Scientific Committee of the European Crohn\u2019s and Colitis Organization (2011) Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease J Crohns Colitis 5:477\u2013483"},{"key":"5234_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-230X-12-47","volume":"12","author":"MA Vazquez","year":"2012","unstructured":"Vazquez MA, Lopez E, Montoya MJ, Giner M, Perez-Temprano R, Perez-Cano R (2012) Vertebral fractures in patients with inflammatory bowel disease compared with a healthy population: a prospective case-control study. BMC Gastroenterol 12:47","journal-title":"BMC Gastroenterol"},{"key":"5234_CR17","doi-asserted-by":"crossref","unstructured":"Li C, Huang Q, Yang R, Dai Y, Zeng Y, Tao L, Li X, Zeng J, Wang Q (2019) Gut microbiota composition and bone mineral loss-epidemiologic evidence from individuals in Wuhan, China. Osteoporos Int","DOI":"10.1007\/s00198-019-04855-5"},{"key":"5234_CR18","doi-asserted-by":"crossref","unstructured":"Chetcuti Zammit S, Ellul P, Girardin G, Valpiani D, Nielsen KR, Olsen J, Goldis A, Lazar D, Shonov\u00e1 O, Nov\u00e1kov\u00e1 M, Sebastian S, Whitehead E, Carmona A, Martinez-Cadilla J, Dahlerup JF, Kievit ALH, Thorsgaard N, Katsanos KH, Christodoulou DK, Magro F, Salupere R, Pedersen N, Kjeldsen J, Carlsen K, Ioannis K, Bergemalm D, Halfvarson J, Duricova D, Bortlik M, Collin P, Oksanen P, Kiudelis G, Kupcinskas L, Kudsk K, Andersen V, O, Morain C, Bailey Y, Doron S, Shmuel O, Almer S, Arebi N, Misra R, \u010cukovi\u0107-\u010cavka S, Brinar M, Munkholm P, Vegh Z, Burisch J (2018) Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. Eur J Gastroenterol Hepatol 30:1297\u20131303","DOI":"10.1097\/MEG.0000000000001238"},{"key":"5234_CR19","doi-asserted-by":"crossref","unstructured":"Briot K, Roux C (2015) Inflammation, bone loss and fracture risk in spondyloarthritis. RMD Open 1:e000052","DOI":"10.1136\/rmdopen-2015-000052"},{"key":"5234_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/jcb.23352","volume":"113","author":"AE Oostlander","year":"2012","unstructured":"Oostlander AE, Everts V, Schoenmaker T, Bravenboer N, van Vliet SJ, van Bodegraven AA, Lips P, de Vries TJ (2012) T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for Crohn\u2019s disease-associated bone loss. J Cell Biochem 113:260\u2013268","journal-title":"J Cell Biochem"},{"key":"5234_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1365-2249.1993.tb05997.x","volume":"94","author":"HC Reinecker","year":"1993","unstructured":"Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn\u2019s disease. Clin Exp Immunol 94:174\u2013181","journal-title":"Clin Exp Immunol"},{"key":"5234_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cytogfr.2011.02.003","volume":"22","author":"MF Neurath","year":"2011","unstructured":"Neurath MF, Finotto S (2011) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22:83\u201389","journal-title":"Cytokine Growth Factor Rev"},{"key":"5234_CR23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/gut.2006.117382","volume":"57","author":"H Tilg","year":"2008","unstructured":"Tilg H, Moschen AR, Kaser A, Pines A, Dotan I (2008) Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57:684\u2013694","journal-title":"Gut"},{"key":"5234_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11914-011-0077-9","volume":"9","author":"M Agrawal","year":"2011","unstructured":"Agrawal M, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, Mechanick JI, Zaidi M (2011) Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep 9:251\u2013257","journal-title":"Curr Osteoporos Rep"},{"key":"5234_CR25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/gut.49.5.644","volume":"49","author":"A Nemetz","year":"2001","unstructured":"Nemetz A, Toth M, Garcia-Gonzalez MA, Zagoni T, Feher J, Pena AS, Tulassay Z (2001) Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut 49:644\u2013649","journal-title":"Gut"},{"key":"5234_CR26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/bjh.12333","volume":"161","author":"M Tucci","year":"2013","unstructured":"Tucci M, Stucci S, Savonarola A, Ciavarella S, Cafforio P, Dammacco F, Silvestris F (2013) Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation. Br J Haematol 161:821\u2013831","journal-title":"Br J Haematol"},{"key":"5234_CR27","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/jcp.25220","volume":"231","author":"S Sprangers","year":"2016","unstructured":"Sprangers S, Schoenmaker T, Cao Y, Everts V, de Vries TJ (2016) Different blood-borne human osteoclast precursors respond in distinct ways to IL-17A. J Cell Physiol 231:1249\u20131260","journal-title":"J Cell Physiol"},{"key":"5234_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.molimm.2017.09.003","volume":"91","author":"R Ganesan","year":"2017","unstructured":"Ganesan R, Rasool M (2017) Interleukin 17 regulates SHP-2 and IL-17RA\/STAT-3 dependent Cyr61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis. Mol Immunol 91:134\u2013144","journal-title":"Mol Immunol"},{"key":"5234_CR29","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.4049\/jimmunol.169.9.4732","volume":"169","author":"H Kitaura","year":"2002","unstructured":"Kitaura H, Nagata N, Fujimura Y, Hotokezaka H, Yoshida N, Nakayama K (2002) Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas\/Fas ligand interaction. J Immunol 169:4732\u20134738","journal-title":"J Immunol"},{"key":"5234_CR30","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.bone.2009.07.079","volume":"45","author":"M Yoshimatsu","year":"2009","unstructured":"Yoshimatsu M, Kitaura H, Fujimura Y, Eguchi T, Kohara H, Morita Y, Yoshida N (2009) IL-12 inhibits TNF-alpha induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone 45:1010\u20131016","journal-title":"Bone"},{"key":"5234_CR31","doi-asserted-by":"publisher","first-page":"R96","DOI":"10.1186\/ar2297","volume":"9","author":"T Yago","year":"2007","unstructured":"Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, Kotake S (2007) IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9:R96","journal-title":"Arthritis Res Ther"},{"key":"5234_CR32","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1002\/eji.200838192","volume":"38","author":"L Chen","year":"2008","unstructured":"Chen L, Wei XQ, Evans B, Jiang W, Aeschlimann D (2008) IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol 38:2845\u20132854","journal-title":"Eur J Immunol"},{"key":"5234_CR33","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.4238\/2014.June.18.10","volume":"13","author":"YK Kang","year":"2014","unstructured":"Kang YK, Zhang MC (2014) IL-23 promotes osteoclastogenesis in osteoblast-osteoclast co-culture system. Genet Mol Res 13:4673\u20134679","journal-title":"Genet Mol Res"},{"key":"5234_CR34","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1002\/eji.200526141","volume":"35","author":"S Kotake","year":"2005","unstructured":"Kotake S, Nanke Y, Mogi M, Kawamoto M, Furuya T, Yago T, Kobashigawa T, Togari A, Kamatani N (2005) IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol 35:3353\u20133363","journal-title":"Eur J Immunol"},{"key":"5234_CR35","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1359\/jbmr.2003.18.6.984","volume":"18","author":"D Mirosavljevic","year":"2003","unstructured":"Mirosavljevic D, Quinn JM, Elliott J, Horwood NJ, Martin TJ, Gillespie MT (2003) T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res 18:984\u2013993","journal-title":"J Bone Miner Res"},{"key":"5234_CR36","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1359\/jbmr.080203","volume":"23","author":"NC Stein","year":"2008","unstructured":"Stein NC, Kreutzmann C, Zimmermann SP, Niebergall U, Hellmeyer L, Goettsch C, Schoppet M, Hofbauer LC (2008) Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. J Bone Miner Res 23:750\u2013758","journal-title":"J Bone Miner Res"},{"key":"5234_CR37","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1074\/jbc.M510160200","volume":"281","author":"P Palmqvist","year":"2006","unstructured":"Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lie A, Conaway HH, Lerner UH (2006) Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem 281:2414\u20132429","journal-title":"J Biol Chem"},{"key":"5234_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S8756-3282(00)00449-X","volume":"28","author":"A Frost","year":"2001","unstructured":"Frost A, Jonsson KB, Brandstrom H, Ljunghall S, Nilsson O, Ljunggren O (2001) Interleukin (IL)-13 and IL-4 inhibit proliferation and stimulate IL-6 formation in human osteoblasts: evidence for involvement of receptor subunits IL-13R, IL-13Ralpha, and IL-4Ralpha. Bone 28:268\u2013274","journal-title":"Bone"},{"key":"5234_CR39","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.orthres.2004.02.008","volume":"22","author":"CJ Silfversward","year":"2004","unstructured":"Silfversward CJ, Frost A, Brandstrom H, Nilsson O, Ljunggren O (2004) Interleukin-4 and interleukin-13 potentiate interleukin-1 induced secretion of interleukin-6 in human osteoblast-like cells. J Orthop Res 22:1058\u20131062","journal-title":"J Orthop Res"},{"key":"5234_CR40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/bph.12116","volume":"169","author":"PP Souza","year":"2013","unstructured":"Souza PP, Brechter AB, Reis RI, Costa CA, Lundberg P, Lerner UH (2013) IL-4 and IL-13 inhibit IL-1beta and TNF-alpha induced kinin B1 and B2 receptors through a STAT6-dependent mechanism. Br J Pharmacol 169:400\u2013412","journal-title":"Br J Pharmacol"},{"key":"5234_CR41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1359\/jbmr.2002.17.4.695","volume":"17","author":"FA Sylvester","year":"2002","unstructured":"Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA (2002) Effect of Crohn\u2019s disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 17:695\u2013702","journal-title":"J Bone Miner Res"},{"key":"5234_CR42","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/00005176-200211000-00010","volume":"35","author":"S Varghese","year":"2002","unstructured":"Varghese S, Wyzga N, Griffiths AM, Sylvester FA (2002) Effects of serum from children with newly diagnosed Crohn disease on primary cultures of rat osteoblasts. J Pediatr Gastroenterol Nutr 35:641\u2013648","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5234_CR43","unstructured":"Oostlander AB, N; Lems, WF; Klein-Nulend, J; Schulten, EA; van Bodegraven, AA; Lips, P. (2008) Effect of proinflammatory cytokines and serum of Crohn\u2019s disease patients on primary human osteoblast proliferation. CALCIFIED TISSUE INTERNATIONAL, pp S113-S113"},{"key":"5234_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1053\/j.gastro.2011.06.011","volume":"141","author":"G Karsenty","year":"2011","unstructured":"Karsenty G, Gershon MD (2011) The importance of the gastrointestinal tract in the control of bone mass accrual. Gastroenterology 141:439\u2013442","journal-title":"Gastroenterology"},{"key":"5234_CR45","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nm.2098","volume":"16","author":"VK Yadav","year":"2010","unstructured":"Yadav VK, Balaji S, Suresh PS, Liu XS, Lu X, Li Z, Guo XE, Mann JJ, Balapure AK, Gershon MD, Medhamurthy R, Vidal M, Karsenty G, Ducy P (2010) Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 16:308\u2013312","journal-title":"Nat Med"},{"key":"5234_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.phrs.2018.07.018","volume":"140","author":"B Lavoie","year":"2019","unstructured":"Lavoie B, Roberts JA, Haag MM, Spohn SN, Margolis KG, Sharkey KA, Lian JB, Mawe GM (2019) Gut-derived serotonin contributes to bone deficits in colitis. Pharmacol Res 140:75\u201384","journal-title":"Pharmacol Res"},{"key":"5234_CR47","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ecco-jcc\/jjy025","volume":"12","author":"OH Nielsen","year":"2018","unstructured":"Nielsen OH, Rejnmark L, Moss AC (2018) Role of vitamin D in the natural history of inflammatory bowel disease. J Crohns Colitis 12:742\u2013752","journal-title":"J Crohns Colitis"},{"key":"5234_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bpg.2016.02.007","volume":"30","author":"PR Kiela","year":"2016","unstructured":"Kiela PR, Ghishan FK (2016) Physiology of intestinal absorption and secretion. Best Pract Res Clin Gastroenterol 30:145\u2013159","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"5234_CR49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0016-5085(76)80197-7","volume":"71","author":"EL Krawitt","year":"1976","unstructured":"Krawitt EL, Beeken WL, Janney CD (1976) Calcium absorption in Crohn\u2019s disease. Gastroenterology 71:251\u2013254","journal-title":"Gastroenterology"},{"key":"5234_CR50","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.gtc.2017.08.011","volume":"46","author":"FK Ghishan","year":"2017","unstructured":"Ghishan FK, Kiela PR (2017) Vitamins and minerals in inflammatory bowel disease. Gastroenterol Clin N Am 46:797\u2013808","journal-title":"Gastroenterol Clin N Am"},{"key":"5234_CR51","first-page":"G718","volume":"248","author":"MD Sitrin","year":"1985","unstructured":"Sitrin MD, Pollack KL, Bolt MJ (1985) Intestinal absorption of 1,25-dihydroxyvitamin D3 in the rat. Am J Phys 248:G718\u2013G725","journal-title":"Am J Phys"},{"key":"5234_CR52","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1359\/jbmr.081209","volume":"24","author":"NO Kuchuk","year":"2009","unstructured":"Kuchuk NO, van Schoor NM, Pluijm SM, Chines A, Lips P (2009) Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res 24:693\u2013701","journal-title":"J Bone Miner Res"},{"key":"5234_CR53","doi-asserted-by":"publisher","first-page":"G35","DOI":"10.1152\/ajpgi.00065.2013","volume":"305","author":"CB Larmonier","year":"2013","unstructured":"Larmonier CB, McFadden RM, Hill FM, Schreiner R, Ramalingam R, Besselsen DG, Ghishan FK, Kiela PR (2013) High vitamin D3 diet administered during active colitis negatively affects bone metabolism in an adoptive T cell transfer model. Am J Physiol Gastrointest Liver Physiol 305:G35\u2013G46","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"5234_CR54","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/sj.ejcn.1601049","volume":"54","author":"BJ Geerling","year":"2000","unstructured":"Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ (2000) Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 54:514\u2013521","journal-title":"Eur J Clin Nutr"},{"key":"5234_CR55","doi-asserted-by":"publisher","first-page":"8646495","DOI":"10.1155\/2017\/8646495","volume":"2017","author":"F Scaldaferri","year":"2017","unstructured":"Scaldaferri F, Pizzoferrato M, Lopetuso LR et al (2017) Nutrition and IBD: malnutrition and\/or sarcopenia? A practical guide. Gastroenterol Res Pract 2017:8646495","journal-title":"Gastroenterol Res Pract"},{"key":"5234_CR56","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/apt.13156","volume":"41","author":"RV Bryant","year":"2015","unstructured":"Bryant RV, Ooi S, Schultz CG, Goess C, Grafton R, Hughes J, Lim A, Bartholomeusz FD, Andrews JM (2015) Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther 41:895\u2013906","journal-title":"Aliment Pharmacol Ther"},{"key":"5234_CR57","doi-asserted-by":"crossref","unstructured":"Laakso S, Valta H, Verkasalo M, Toiviainen-Salo S, Makitie O (2014) Compromised peak bone mass in patients with inflammatory bowel disease--a prospective study. J Pediatr 164:1436\u20131443 e1431","DOI":"10.1016\/j.jpeds.2014.01.073"},{"key":"5234_CR58","doi-asserted-by":"crossref","unstructured":"Suibhne TN, Cox G, Healy M, O\u2019Morain C, O\u2019Sullivan M (2012) Vitamin D deficiency in Crohn\u2019s disease: prevalence, risk factors and supplement use in an outpatient setting. J Crohns Colitis 6:182\u2013188","DOI":"10.1016\/j.crohns.2011.08.002"},{"key":"5234_CR59","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.1002\/ibd.22890","volume":"19","author":"HL Miller","year":"2013","unstructured":"Miller HL, Farraye FA, Coukos J, Howard LA, Holick MF, Stucchi AF, Becker JM (2013) Vitamin D deficiency and insufficiency are common in ulcerative colitis patients after ileal pouch-anal anastomosis. Inflamm Bowel Dis 19:E25\u2013E26","journal-title":"Inflamm Bowel Dis"},{"key":"5234_CR60","first-page":"609","volume":"7","author":"H Vogelsang","year":"1995","unstructured":"Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A (1995) Prevention of bone mineral loss in patients with Crohn\u2019s disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 7:609\u2013614","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5234_CR61","doi-asserted-by":"crossref","unstructured":"Melek J, Sakuraba A (2014) Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review. Clin Gastroenterol Hepatol 12:32\u201344 e35","DOI":"10.1016\/j.cgh.2013.08.024"},{"key":"5234_CR62","doi-asserted-by":"crossref","unstructured":"Robinson RJ, Krzywicki T, Almond L, al-Azzawi F, Abrams K, Iqbal SJ, Mayberry JF (1998) Effect of a low-impact exercise program on bone mineral density in Crohn\u2019s disease: a randomized controlled trial. Gastroenterology 115:36\u201341","DOI":"10.1016\/S0016-5085(98)70362-2"},{"key":"5234_CR63","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1080\/003655299750025903","volume":"34","author":"C Schulte","year":"1999","unstructured":"Schulte C, Dignass AU, Mann K, Goebell H (1999) Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol 34:696\u2013702","journal-title":"Scand J Gastroenterol"},{"key":"5234_CR64","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/MOG.0000000000000037","volume":"30","author":"LE Targownik","year":"2014","unstructured":"Targownik LE, Bernstein CN, Leslie WD (2014) Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol 30:168\u2013174","journal-title":"Curr Opin Gastroenterol"},{"key":"5234_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1365-2036.1998.00271.x","volume":"12","author":"RJ Robinson","year":"1998","unstructured":"Robinson RJ, Iqbal SJ, Al-Azzawi F, Abrams K, Mayberry JF (1998) Sex hormone status and bone metabolism in men with Crohn\u2019s disease. Aliment Pharmacol Ther 12:21\u201325","journal-title":"Aliment Pharmacol Ther"},{"key":"5234_CR66","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1097\/MIB.0000000000000962","volume":"22","author":"GA Tew","year":"2016","unstructured":"Tew GA, Jones K, Mikocka-Walus A (2016) Physical activity habits, limitations, and predictors in people with inflammatory bowel disease: a large cross-sectional online survey. Inflamm Bowel Dis 22:2933\u20132942","journal-title":"Inflamm Bowel Dis"},{"key":"5234_CR67","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.40137","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA et al (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69:1521\u20131537","journal-title":"Arthritis Rheumatol"},{"key":"5234_CR68","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000091299","volume":"24","author":"P Miheller","year":"2006","unstructured":"Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z (2006) Infliximab therapy improves the bone metabolism in fistulizing Crohn\u2019s disease. Dig Dis 24:201\u2013206","journal-title":"Dig Dis"},{"key":"5234_CR69","doi-asserted-by":"crossref","unstructured":"Veerappan SG, O\u2019Morain CA, Daly JS, Ryan BM (2011) Review article: the effects of antitumour necrosis factor-alpha on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 33:1261\u20131272","DOI":"10.1111\/j.1365-2036.2011.04667.x"},{"key":"5234_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10620-015-3838-y","volume":"61","author":"K Sugimoto","year":"2016","unstructured":"Sugimoto K, Ikeya K, Iida T et al (2016) An increased serum N-terminal telopeptide of type I collagen, a biochemical marker of increased bone resorption, is associated with infliximab therapy in patients with Crohn\u2019s disease. Dig Dis Sci 61:99\u2013106","journal-title":"Dig Dis Sci"},{"key":"5234_CR71","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.crohns.2014.08.004","volume":"8","author":"A Krajcovicova","year":"2014","unstructured":"Krajcovicova A, Hlavaty T, Killinger Z et al (2014) Combination therapy with an immunomodulator and anti-TNFalpha agent improves bone mineral density in IBD patients. J Crohns Colitis 8:1693\u20131701","journal-title":"J Crohns Colitis"},{"key":"5234_CR72","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/ajcn\/54.3.548","volume":"54","author":"GA Leichtmann","year":"1991","unstructured":"Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD (1991) Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn\u2019s disease and intestinal resection. Am J Clin Nutr 54:548\u2013552","journal-title":"Am J Clin Nutr"},{"key":"5234_CR73","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.crohns.2012.06.003","volume":"7","author":"SF Bakker","year":"2013","unstructured":"Bakker SF, Dik VK, Witte BI, Lips P, Roos JC, Van Bodegraven AA (2013) Increase in bone mineral density in strictly treated Crohn\u2019s disease patients with concomitant calcium and vitamin D supplementation. J Crohns Colitis 7:377\u2013384","journal-title":"J Crohns Colitis"},{"key":"5234_CR74","doi-asserted-by":"crossref","unstructured":"Raftery T, O\u2019Morain CA, O\u2019Sullivan M (2012) Vitamin D: new roles and therapeutic potential in inflammatory bowel disease. Curr Drug Metab 13:1294\u20131302","DOI":"10.2174\/138920012803341294"},{"key":"5234_CR75","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1046\/j.1365-2036.1996.63205000.x","volume":"10","author":"CN Bernstein","year":"1996","unstructured":"Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F (1996) A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 10:777\u2013786","journal-title":"Aliment Pharmacol Ther"},{"key":"5234_CR76","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/MPG.0b013e3180dca0cc","volume":"45","author":"EI Benchimol","year":"2007","unstructured":"Benchimol EI, Ward LM, Gallagher JC, Rauch F, Barrowman N, Warren J, Beedle S, Mack DR (2007) Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 45:538\u2013545","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5234_CR77","doi-asserted-by":"publisher","first-page":"2736547","DOI":"10.1155\/2017\/2736547","volume":"2017","author":"Y Hu","year":"2017","unstructured":"Hu Y, Chen X, Chen X, Zhang S, Jiang T, Chang J, Gao Y (2017) Bone loss prevention of bisphosphonates in patients with inflammatory bowel disease: a systematic review and meta-analysis. Can J Gastroenterol Hepatol 2017:2736547","journal-title":"Can J Gastroenterol Hepatol"},{"key":"5234_CR78","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1136\/gutjnl-2013-305523","volume":"63","author":"AA van Bodegraven","year":"2014","unstructured":"van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude C, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand R, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P, Dutch Initiative on Crohn and Colitis (ICC) (2014) Treatment of bone loss in osteopenic patients with Crohn\u2019s disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. Gut 63:1424\u20131430","journal-title":"Gut"},{"key":"5234_CR79","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","volume":"22","author":"S Ferrari-Lacraz","year":"2011","unstructured":"Ferrari-Lacraz S, Ferrari S (2011) Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int 22:435\u2013446","journal-title":"Osteoporos Int"},{"key":"5234_CR80","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00223-018-0401-9","volume":"102","author":"AM Dubrovsky","year":"2018","unstructured":"Dubrovsky AM, Lim MJ, Lane NE (2018) Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton. Calcif Tissue Int 102:607\u2013618","journal-title":"Calcif Tissue Int"},{"key":"5234_CR81","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/14397595.2016.1232776","volume":"27","author":"H Kinoshita","year":"2017","unstructured":"Kinoshita H, Miyakoshi N, Kashiwagura T, Kasukawa Y, Sugimura Y, Shimada Y (2017) Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis. Mod Rheumatol 27:582\u2013586","journal-title":"Mod Rheumatol"},{"key":"5234_CR82","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723\u20131732","journal-title":"Osteoporos Int"},{"key":"5234_CR83","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI3914","volume":"102","author":"NE Lane","year":"1998","unstructured":"Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627\u20131633","journal-title":"J Clin Invest"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05234-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-05234-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05234-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T20:27:25Z","timestamp":1607459245000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-05234-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["5234"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-05234-w","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"2 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}